Recent Updates
Recently added Catalysts
SEER Positive Sentiment

Seer to Report First Quarter 2024 Financial Results on May 8, 2024

Key Takeaway: Seer, Inc. has announced its intention to report financial results for the first quarter of 2024 on May 8, 2024. The company, known for its advancements in proteomics, will host a conference call to discuss these results. Interested parties can access the live webcast on Seer's investor website, with an archived replay to be made available afterward. The company continues to focus on developing products that improve proteomic analysis capabilities.
Price reaction · baseline $1.67 (2024-04-22 close) · hit after-hours · clean, no other SEER news in the window
day 0 close
+8.4%
day 1
+6%
day 3 · peak
+14.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seer is a leading company in life sciences commercialization.
  • The Proteograph Product Suite offers innovative solutions for proteomic analysis.
  • The upcoming webcast demonstrates transparency and investor engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~65 mo
Minimal dilution risk
Lead asset
standardized turmeric root extract
Phase 1 · Cystic Fibrosis

Full Press Release Details

REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Frequently Asked Questions

When will Seer, Inc. report its Q1 2024 financial results?

Seer, Inc. will report its Q1 2024 financial results on May 8, 2024.

What time is the conference call for Seer's financial report?

The conference call will start at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

How can I access the live webcast for Seer's financial results?

The live webcast will be available on the Investor section of Seer’s website.

What is Seer's Proteograph Product Suite used for?

Seer's Proteograph Product Suite is used for deep, unbiased proteomic analysis.

Is the Proteograph Product Suite intended for diagnostic procedures?

No, the Proteograph Product Suite is for research use only and not for diagnostics.

Last updated: Apr 23, 2024